Advertisement

Topics

Screening Of Adult urBan pOpulation To diAgnose Heart Failure

2018-05-21 18:19:10 | BioPortfolio

Published on BioPortfolio: 2018-05-21T18:19:10-0400

Clinical Trials [2438 Associated Clinical Trials listed on BioPortfolio]

Effect of NT-proBNP Guided Treatment of Chronic Heart Failure

The purpose of this study is to determine whether NT-proBNP guided treatment of chronic congestive heart failure will reduce heart failure related morbidity and mortality compared to thera...

Early Management Strategies of Acute Heart Failure for Patients With NSTEMI

There are always poor outcomes in patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level. An elevated BNP/NT-proBNP level highly indicates acute heart fa...

Karolinska-Rennes (KaRen) Prospective Study of Exercise Stress Echocardiography in Heart Failure With Preserved Ejection Fraction

Background: Heart failure with preserved ejection fraction (HFPEF) is common but not well understood. Electrical dyssynchrony in systolic heart failure is harmful. Little is known about t...

A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care

This low interventional study, whose unique intervention will be to measure the blood level of a biomarker called NT-proBNP in chronic heart failure patients daily followed-up by Primary C...

VITROS Immunodiagnostic Products NT-proBNP II

Amino Terminal pro-Brain Natriuretic Peptide (NTproBNP) is secreted in conditions of cardiac wall stress. NTproBNP levels are used in addition to clinical assessment to diagnose heart fail...

PubMed Articles [7003 Associated PubMed Articles listed on BioPortfolio]

Renal function, N-Terminal Pro-B-Type Natriuretic Peptide, Propeptide Big-Endothelin and patients with heart failure and preserved ejection fraction.

Renal dysfunction may limit the clinical application of NT-proBNP in the diagnosis of heart failure. In general practice, where echocardiography is not readily available, a biomarker for the diagnosis...

A comparison of the prognostic value of BNP versus NT-proBNP after hospitalisation for heart failure.

Concentrations of circulating B‑type natriuretic peptides provide important prognostic information in heart failure (HF) patients. We directly compared the prognostic performance of brain natriureti...

Semaphorin 4D levels in heart failure patients: a potential novel biomarker of acute heart failure?

Semaphorin 4D (Sema4D) is expressed on platelets and T-cells and known to be involved in inflammation. The aims of this study include comparing Sema4D and N terminal pro brain natriuretic peptide (NT-...

NT-proBNP: When is it useful in Obstetric Medicine?

Pregnancy, viewed as a stress test of the haemodynamic system, may unmask underlying cardiac disease. Pregnancy may also induce de novo cardiac disease. N-terminal brain-type natriuretic peptide (NT-...

Atrial and brain natriuretic peptides: hormones secreted from the heart.

The natriuretic peptide family consists of three biologically active peptides: atrial natriuretic peptide (ANP), brain (B-type) natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). Among t...

Medical and Biotech [MESH] Definitions

Echocardiography amplified by the addition of depth to the conventional two-dimensional ECHOCARDIOGRAPHY visualizing only the length and width of the heart. Three-dimensional ultrasound imaging was first described in 1961 but its application to echocardiography did not take place until 1974. (Mayo Clin Proc 1993;68:221-40)

A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.

Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.

Heart failure caused by abnormal myocardial contraction during SYSTOLE leading to defective cardiac emptying.

Heart failure caused by abnormal myocardial relaxation during DIASTOLE leading to defective cardiac filling.

More From BioPortfolio on "Screening Of Adult urBan pOpulation To diAgnose Heart Failure"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial